Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 13
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo científico (JournalArticle)

Gain-of-function mutations in DNMT3A in patients with paraganglioma.

  • Remacha, Laura
  • Currás-Freixes, Maria
  • Torres-Ruiz, Raúl
  • Schiavi, Francesca
  • Torres-Pérez, Rafael
  • Calsina, Bruna
  • Letón, Rocío
  • Comino-Méndez, Iñaki
  • Roldán-Romero, Juan M
  • Montero-Conde, Cristina
  • Santos, María
  • Pérez, Lucía Inglada
  • Pita, Guillermo
  • Alonso, María R
  • Honrado, Emiliano
  • Pedrinaci, Susana
  • Crespo-Facorro, Benedicto
  • Percesepe, Antonio
  • Falcioni, Maurizio
  • Rodríguez-Perales, Sandra
  • Korpershoek, Esther
  • Ramón-Maiques, Santiago
  • Opocher, Giuseppe
  • Rodríguez-Antona, Cristina
  • Robledo Batanero, Mercedes
  • Cascon Soriano, Alberto
The high percentage of patients carrying germline mutations makes pheochromocytomas/paragangliomas the most heritable of all tumors. However, there are still cases unexplained by mutations in the known genes. We aimed to identify the genetic cause of disease in patients strongly suspected of having hereditary tumors.
Repisalud
Publicación Artículo científico (JournalArticle)

Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paraganglioma

  • Calsina, Bruna
  • Castro-Vega, Luis Jaime
  • Torres-Pérez, Rafael
  • Inglada Perez, Lucia
  • Currás-Freixes, Maria
  • Roldán-Romero, Juan María
  • Mancikova, Veronika
  • Letón, Rocío
  • Remacha, Laura
  • Santos, María
  • Burnichon, Nelly
  • Lussey-Lepoutre, Charlotte
  • Rapizzi, Elena
  • Graña, Osvaldo
  • Álvarez-Escolá, Cristina
  • de Cubas, Aguirre A
  • Lanillos, Javier
  • Cordero-Barreal, Alfonso
  • Martínez-Montes, Ángel M
  • Bellucci, Alexandre
  • Amar, Laurence
  • Fernandes-Rosa, Fabio Luiz
  • Calatayud, María
  • Aller, Javier
  • Lamas, Cristina
  • Sastre-Marcos, Júlia
  • Canu, Letizia
  • Korpershoek, Esther
  • Timmers, Henri J
  • Lenders, Jacques Wm
  • Beuschlein, Felix
  • Fassnacht-Capeller, Martin
  • Eisenhofer, Graeme
  • Mannelli, Massimo
  • Al-Shahrour, Fatima
  • Favier, Judith
  • Rodriguez Antona, Cristina
  • Cascon Soriano, Alberto
  • Montero-Conde, Cristina
  • Gimenez-Roqueplo, Anne-Paule
  • Robledo Mercedes, Mercedes
Rationale: Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors that present variable outcomes. To date, no effective therapies or reliable prognostic markers are available for patients who develop metastatic PPGL (mPPGL). Our aim was to discover robust prognostic markers validated through in vitro models, and define specific therapeutic options according to tumor genomic features. Methods: We analyzed three PPGL miRNome datasets (n=443), validated candidate markers and assessed them in serum samples (n=36) to find a metastatic miRNA signature. An integrative study of miRNome, transcriptome and proteome was performed to find miRNA targets, which were further characterized in vitro. Results: A signature of six miRNAs (miR-21-3p, miR-183-5p, miR-182-5p, miR-96-5p, miR-551b-3p, and miR-202-5p) was associated with metastatic risk and time to progression. A higher expression of five of these miRNAs was also detected in PPGL patients' liquid biopsies compared with controls. The combined expression of miR-21-3p/miR-183-5p showed the best power to predict metastasis (AUC=0.804, P=4.67·10-18), and was found associated in vitro with pro-metastatic features, such as neuroendocrine-mesenchymal transition phenotype, and increased cell migration rate. A pan-cancer multi-omic integrative study correlated miR-21-3p levels with TSC2 expression, mTOR pathway activation, and a predictive signature for mTOR inhibitor-sensitivity in PPGLs and other cancers. Likewise, we demonstrated in vitro a TSC2 repression and an enhanced rapamycin sensitivity upon miR-21-3p expression. Conclusions: Our findings support the assessment of miR-21-3p/miR-183-5p, in tumors and liquid biopsies, as biomarkers for risk stratification to improve the PPGL patients' management. We propose miR-21-3p to select mPPGL patients who may benefit from mTOR inhibitors.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Cost-Utility of Mindfulness-Based Stress Reduction for Fibromyalgia versus a Multicomponent Intervention and Usual Care: A 12-Month Randomized Controlled Trial (EUDAIMON Study)

  • Perez-Aranda, A.
  • D''Amico, F.
  • Feliu-Soler, A.
  • McCracken, L.M.
  • Penarrubia-Maria, M.T.
  • Andres-Rodriguez, L.
  • Angarita-Osorio, N.
  • Knapp, M.
  • Garcia-Campayo, J.
  • Luciano, J.V.
Fibromyalgia (FM) is a prevalent, chronic, disabling, pain syndrome that implies high healthcare costs. Economic evaluations of potentially effective treatments for FM are needed. The aim of this study was to analyze the cost-utility of Mindfulness-Based Stress Reduction (MBSR) as an add-on to treatment-as-usual (TAU) for patients with FM compared to an adjuvant multicomponent intervention (FibroQoL) and to TAU. We performed an economic evaluation alongside a 12 month, randomized, controlled trial; data from 204 (68 per study arm) of the 225 patients (90.1%) were included in the cost-utility analyses, which were conducted both under the government and the public healthcare system perspectives. The main outcome measures were the EuroQol (EQ-5D-5L) for assessing Quality-Adjusted Life Years (QALYs) and improvements in health-related quality of life, and the Client Service Receipt Inventory (CSRI) for estimating direct and indirect costs. Incremental cost-effectiveness ratios (ICERs) were also calculated. Two sensitivity analyses (intention-to-treat, ITT, and per protocol, PPA) were conducted. The results indicated that MBSR achieved a significant reduction in costs compared to the other study arms (p < 0.05 in the completers sample), especially in terms of indirect costs and primary healthcare services. It also produced a significant incremental effect compared to TAU in the ITT sample (Delta QALYs = 0.053, p < 0.05, where QALYs represents quality-adjusted life years). Overall, our findings support the efficiency of MBSR over FibroQoL and TAU specifically within a Spanish public healthcare context.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer

  • Codony-Servat, Jordi
  • Cuatrecasas, Miriam|||0000-0003-3063-0110
  • Asensio, Elena
  • Montironi, Carla|||0000-0002-1453-2193
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Marín Aguilera, Mercedes
  • Horndler, Carlos
  • Martínez Balibrea, Eva|||0000-0002-4501-7100
  • Rubini, Michele
  • Jares, Pedro
  • Reig, Oscar|||0000-0003-1166-6943
  • Victoria, Iván
  • Gaba, Lydia
  • Martín-Richard, Marta|||0000-0003-4933-2463
  • Alonso Orduña, Vicente|||0000-0003-2280-1004
  • Escudero, Pilar
  • Fernández-Martos, Carlos
  • Feliu, Jaime|||0000-0003-4867-1420
  • Méndez, Jose Carlos
  • Méndez, Miguel
  • Gallego Plazas, Javier|||0000-0002-0584-1242
  • Salud, Antonieta
  • Rojo, Federico|||0000-0001-9989-0290
  • Castells, Antoni|||0000-0001-8431-2033
  • Prat, Aleix|||0000-0003-2377-540X
  • Rosell, Rafael|||0000-0003-0817-3400
  • García-Albéniz, Xabier
  • Camps Polo, Jordi|||0000-0003-2929-4228
  • Maurel, Joan|||0000-0002-9413-5592
Although chemotherapy is the cornerstone treatment for patients with metastatic colorectal cancer (mCRC), acquired chemoresistance is common and constitutes the main reason for treatment failure. Monoclonal antibodies against insulin-like growth factor-1 receptor (IGF-1R) have been tested in pre-treated mCRC patients, but results have been largely deceiving. We analysed time to progression, overall survival, and the mutational status of RAS, BRAF and nuclear p-IGF-1R expression by immunohistochemistry, in 470 metastatic CRC patients. The effect of IGF-1R activation and distribution was also assessed using cellular models of CRC and RNAi for functional validation. Nuclear IGF-1R increased in metastatic tumours compared to paired untreated primary tumours, and significantly correlated with poor overall survival in mCRC patients. In vitro, chemo-resistant cell lines presented significantly higher levels of IGF-1R expression within the nuclear compartment, and PIAS3, a protein implicated also in the sumoylation process of intranuclear proteins, contributed to IGF-1R nuclear sequestration, highlighting the essential role of PIAS3 in this process. Intriguingly, we observed that ganitumab, an IGF-1R blocking-antibody used in several clinical trials, and dasatinib, an SRC inhibitor, increased the nuclear localisation of IGF-1R. Our study demonstrates that IGF-1R nuclear location might lead to chemotherapy and targeted agent resistance.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Machine learning to understand the immune-inflammatory pathways in fibromyalgia

  • Andrés Rodríguez, Laura|||0000-0001-5133-9811
  • Borràs, Xavier|||0000-0003-3972-1385
  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Pérez-Aranda, Adrián|||0000-0002-1602-3413
  • Rozadilla-Sacanell, Antoni|||0000-0002-7555-189X
  • Arranz, Belén|||0000-0003-3927-8803
  • Montero-Marín, Jesús|||0000-0001-5677-1662
  • Garcia-Campayo, Javier|||0000-0002-3797-4218
  • Angarita-Osorio, Natalia|||0000-0001-8925-2754
  • Maes, Michael|||0000-0002-2012-871X
  • Luciano, Juan Vicente|||0000-0003-0750-1599
Fibromyalgia (FM) is a chronic syndrome characterized by widespread musculoskeletal pain, and physical and emotional symptoms. Although its pathophysiology is largely unknown, immune-inflammatory pathways may be involved. We examined serum interleukin (IL)-6, high sensitivity C-reactive protein (hs-CRP), CXCL-8, and IL-10 in 67 female FM patients and 35 healthy women while adjusting for age, body mass index (BMI), and comorbid disorders. We scored the Fibromyalgia Severity Score, Widespread Pain Index (WPI), Symptom Severity Scale (SSS), Hospital Anxiety (HADS-A), and Depression Scale and the Perceived Stress Scale (PSS-10). Clinical rating scales were significantly higher in FM patients than in controls. After adjusting for covariates, IL-6, IL-10, and CXCL-8 were lower in FM than in HC, whereas hs-CRP did not show any difference. Binary regression analyses showed that the diagnosis FM was associated with lowered IL-10, quality of sleep, aerobic activities, and increased HADS-A and comorbidities. Neural networks showed that WPI was best predicted by quality of sleep, PSS-10, HADS-A, and the cytokines, while SSS was best predicted by PSS-10, HADS-A, and IL-10. Lowered levels of cytokines are associated with FM independently from confounders. Lowered IL-6 and IL-10 signaling may play a role in the pathophysiology of FM.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Effects of attachment-based compassion therapy (ABCT) on brain-derived neurotrophic factor and low-grade inflammation among fibromyalgia patients, a randomized controlled trial

  • Montero-Marín, Jesús|||0000-0001-5677-1662
  • Andrés Rodríguez, Laura|||0000-0001-5133-9811
  • Tops, Mattie
  • Luciano, Juan Vicente|||0000-0003-0750-1599
  • Navarro-Gil, Mayte|||0000-0003-4842-0453
  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • López-del-Hoyo, Yolanda|||0000-0002-1690-4130
  • Garcia-Campayo, Javier|||0000-0002-3797-4218
Fibromyalgia (FM) is a disabling syndrome characterized by chronic pain associated with fatigue. Its pathogenesis is unknown, but alterations in central sensitization, involving an imbalance of brain-derived neurotrophic factor (BDNF) and inflammatory biomarkers, appear to be implicated. The aim of this study was to evaluate the impact of attachment-based compassion therapy (ABCT) on levels of BDNF, the inflammatory markers TNF-α, IL-6, IL-10, and the C-reactive protein (CRP), analysing whether biomarkers play a mediating/moderating role in improvements in FM functional status. Thirty-four female patients with FM participated in a RCT and were assigned to ABCT or relaxation therapy. Blood extractions were conducted at baseline and post-intervention, with self-report assessments of functional status (FIQ) at baseline, post-intervention and 3-month follow-up. A pro-inflammatory composite was obtained by summing up IL-6, TNF-α and CRP normalized values. Non-parametric tests, analysis of variance and regression models were used to evaluate treatment and mediation/moderation. Compared to relaxation therapy, ABCT showed significant improvements in FIQ and decreases in BDNF, CRP, and pro-inflammatory composite. Changes in BDNF had a mediating role in FIQ. ABCT seems to reduce BDNF and appears to have anti-inflammatory effects in FM patients. Reductions in BDNF could be a mechanism of FM functional status improvement. Clinical Trial Registration:http://ClinicalTrials.gov, identifier NCT02454244. Date: May 27th, 2015.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Quantitative analysis of somatically acquired and constitutive uniparental disomy in gastrointestinal cancers

  • Torabi Asensio, Keyvan|||0000-0002-9067-0061
  • Erola, Pau
  • Álvarez Mora, María Isabel|||0000-0003-3788-8915
  • Díaz-Gay, Marcos|||0000-0003-0658-0467
  • Ferrer Menduiña, Queralt|||0000-0003-3177-4618
  • Castells, Antoni|||0000-0001-8431-2033
  • Castellví-Bel, Sergi|||0000-0003-1217-5097
  • Milà, Montserrat
  • Lozano, Juan José
  • Miró Ametller, Rosa|||0000-0003-2508-5074
  • Ried, Thomas|||0000-0002-0767-6009
  • Ponsa Arjona, Immaculada|||0000-0003-3436-1907
  • Camps Polo, Jordi|||0000-0003-2929-4228
Somatically acquired uniparental disomies (aUPDs) are frequent events in solid tumors and have been associated with cancer-related genes. Studies assessing their functional consequences across several cancer types are therefore necessary. Here, we aimed at integrating aUPD profiles with the mutational status of cancer-related genes in a tumor-type specific manner. Using TCGA datasets for 1,032 gastrointestinal cancers, including colon (COAD), rectum (READ), stomach (STAD), esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESCC), we show a non-random distribution of aUPD, suggesting the existence of a cancer-specific landscape of aUPD events. Our analysis indicates that aUPD acts as a "second hit" in Knudson's model in order to achieve biallelic inactivation of tumor suppressor genes. In particular, APC , ARID1A and NOTCH1 were recurrently inactivated by the presence of homozygous mutation as a consequence of aUPD in COAD and READ, STAD and ESCC, respectively. Furthermore, while TP53 showed inactivation caused by aUPD at chromosome arm 17p across all tumor types, copy number losses at this genomic position were also frequent. By experimental and computationally inferring genome ploidy, we demonstrate that an increased number of aUPD events, both affecting the whole chromosome or segments of it, were present in highly aneuploid genomes compared to near-diploid tumors. Finally, the presence of mosaic UPD was detected at a higher frequency in DNA extracted from peripheral blood lymphocytes of patients with colorectal cancer compared to healthy individuals. In summary, our study defines specific profiles of aUPD in gastrointestinal cancers and provides unequivocal evidence of their relevance in cancer.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

CNApp, a tool for the quantification of copy number alterations and integrative analysis revealing clinical implications

  • Franch-Expósito, Sebastià|||0000-0002-4542-1701
  • Bassaganyas, Laia|||0000-0002-4575-0214
  • Vila-Casadesús, Maria|||0000-0001-6597-7953
  • Hernández-Illán, Eva
  • Esteban-Fabró, Roger
  • Díaz-Gay, Marcos|||0000-0003-0658-0467
  • Lozano, Juan José
  • Castells, Antoni|||0000-0001-8431-2033
  • Llovet, Josep Maria
  • Castellví-Bel, Sergi|||0000-0003-1217-5097
  • Camps Polo, Jordi|||0000-0003-2929-4228
Somatic copy number alterations (CNAs) are a hallmark of cancer, but their role in tumorigenesis and clinical relevance remain largely unclear. Here, we developed CNApp, a web-based tool that allows a comprehensive exploration of CNAs by using purity-corrected segmented data from multiple genomic platforms. CNApp generates genome-wide profiles, computes CNA scores for broad, focal and global CNA burdens, and uses machine learning-based predictions to classify samples. We applied CNApp to the TCGA pan-cancer dataset of 10,635 genomes showing that CNAs classify cancer types according to their tissue-of-origin, and that each cancer type shows specific ranges of broad and focal CNA scores. Moreover, CNApp reproduces recurrent CNAs in hepatocellular carcinoma and predicts colon cancer molecular subtypes and microsatellite instability based on broad CNA scores and discrete genomic imbalances. In summary, CNApp facilitates CNA-driven research by providing a unique framework to identify relevant clinical implications. CNApp is hosted at . In most cases, human cells contain two copies of each of their genes, yet sometimes this can change, an effect called copy number alteration (CNA). Cancer is a genetic disease and thus, studying the DNA from tumor samples is crucial to improving diagnosis and choosing the right treatment. Most tumors contain cells with CNAs; however, the impact of CNAs in cancer progression is poorly understood. CNAs can be studied by examining the genome of tumor cells and finding which regions display an unusual number of copies. It may also be possible to gather information about different cancer types by analyzing the CNAs in a tumor, but this approach requires the analysis of large amounts of data. To aid the analysis of CNAs in cancer cells, Franch-Expósito, Bassaganyas et al. have created an online tool called CNApp, which is able to identify and count CNAs in genomic data and link them to features associated with different cancers. The hope is that a better understanding of the effect of CNAs in cancer could help better diagnose cancers, and improve outcomes for patients. Potentially, this could also predict what type of treatment would work better for a specific tumor. Besides, by using a machine-learning approach, the tool can also make predictions about specific cancer subtypes in order to facilitate clinical decisions. Franch-Expósito, Bassaganyas et al. tested CNApp using previously existing cancer data from 33 different cancer types to show how CNApp can help the interpretation of CNAs in cancer. Moreover, CNApp can also use CNAs to identify different types of bowel (colorectal) cancer in a way that could help doctors to make decisions about treatment. Together these findings show that CNApp provides an adaptable and accessible research tool for the study of cancer genomics, which could provide opportunities to inform medical procedures.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Tetraploidy-associated genetic heterogeneity confers chemo-radiotherapy resistance to colorectal cancer cells

  • Galofré, Claudia|||0000-0003-4415-4987
  • Gönül Geyik, Öykü
  • Asensio, Elena
  • Wangsa, Darawalee
  • Hirsch, Daniela|||0000-0001-8883-922X
  • Parra, Carolina
  • Saez, Jordi|||0000-0003-4888-9323
  • Mollà, Meritxell|||0000-0001-6215-2251
  • Yüce, Zeynep
  • Castells, Antoni|||0000-0001-8431-2033
  • Ried, Thomas|||0000-0002-0767-6009
  • Camps Polo, Jordi|||0000-0003-2929-4228
Tetraploidy, or whole-genome duplication, is a common phenomenon in cancer and preludes chromosome instability, which strongly correlates with disease progression, metastasis, and treatment failure. Therefore, it is reasonable to hypothesize that tetraploidization confers multidrug resistance. Nevertheless, the contribution of whole-genome duplication to chemo-radiotherapy resistance remains unclear. Here, using isogenic diploid and near-tetraploid clones from three colorectal cancer cell lines and one non-transformed human epithelial cell line, we show a consistent growth impairment but a divergent tumorigenic potential of near-tetraploid cells. Next, we assessed the effects of first-line chemotherapeutic drugs, other commonly used agents and ionizing radiation, and found that whole-genome duplication promoted increased chemotherapy resistance and also conferred protection against irradiation. When testing the activation of apoptosis, we observed that tetraploid cells were less prone to caspase 3 activation after treatment with first-line chemotherapeutic agents. Furthermore, we found that pre-treatment with ataxia telangiectasia and Rad3 related (ATR) inhibitors, which targets response to replication stress, significantly enhanced the sensitivity of tetraploid cells to first-line chemotherapeutic agents as well as to ionizing radiation. Our findings provide further insight into how tetraploidy results in greater levels of tolerance to chemo-radiotherapeutic agents and, moreover, we show that ATR inhibitors can sensitize near-tetraploid cells to commonly used chemo-radiotherapy regimens.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Centrosome reduction in newly-generated tetraploid cancer cells obtained by separase depletion

  • Galofré, Claudia|||0000-0003-4415-4987
  • Asensio, Elena
  • Ubach, Maria
  • Torres, Irianna M.
  • Quintanilla, Isabel
  • Castells, Antoni|||0000-0001-8431-2033
  • Camps Polo, Jordi|||0000-0003-2929-4228
Tetraploidy, a common feature in cancer, results in the presence of extra centrosomes, which has been associated with chromosome instability (CIN) and aneuploidy. Deregulation in the number of centrosomes triggers tumorigenesis. However, how supernumerary centrosomes evolve during the emergence of tetraploid cells remains yet to be elucidated. Here, generating tetraploid isogenic clones in colorectal cancer and in non-transformed cells, we show that near-tetraploid clones exhibit a significant increase in the number of centrosomes. Moreover, we find that centrosome area in near-tetraploids is twice as large as in near-diploids. To evaluate whether centrosome clustering was occurring, we next analysed the number of centrioles revealing centriole amplification. Notwithstanding, more than half of the near-tetraploids maintained in culture do not present centrosome aberrations. To test whether cells progressively lost centrioles after becoming near-tetraploid, we transiently transfected diploid cells with siRNA against ESPL1 /Separase, a protease responsible for triggering anaphase, to generate newly near-tetraploid cells. Finally, using this model, we assessed the number of centrioles at different time-points after tetraploidization finding that near-tetraploids rapidly lose centrosomes over time. Taken together, these data demonstrate that although most cells reduce supernumerary centrosomes after tetraploidization, a small fraction retains extra centrioles, potentially resulting in CIN.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Patients with fibromyalgia reporting severe pain but low impact of the syndrome, clinical and pain-related cognitive features

  • Angarita-Osorio, Natalia|||0000-0001-8925-2754
  • Pérez-Aranda, Adrián|||0000-0002-1602-3413
  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Andrés Rodríguez, Laura|||0000-0001-5133-9811
  • Borràs, Xavier|||0000-0003-3972-1385
  • Suso-Ribera, Carlos|||0000-0002-2655-1017
  • Slim, Mahmoud|||0000-0003-2455-1432
  • Herrera-Mercadal, Paola|||0000-0003-2088-4272
  • Fernández Vergel, Rita|||0000-0003-2469-1224
  • Blanco, M. Elena
  • Luciano, Juan Vicente|||0000-0003-0750-1599
Background: Fibromyalgia (FM) is a prevalent and highly disabling chronic pain syndrome. However, differences among patients regarding how pain impacts on daily life are remarkable. The main aim of this study was to identify clinical and pain-related cognitive variables characterizing patients reporting high adaptability despite experiencing severe chronic pain. Methods: 283 Spanish patients with FM with high levels of pain were classified on two groups: (1) those reporting low impact of the syndrome, and (2) those with moderate-to-high impact. Perceived stress, anxiety, and depressive symptoms along with pain catastrophizing, psychological inflexibility, and perceived control over pain were evaluated. Differences in sociodemographics, years with FM, past/current major depressive disorder comorbidity, and health-related economic costs (i.e. medications, use of medical services, lost productivity due to sick leave) were also assessed. Stepwise logistic regression analyses predicting group membership from clinical variables and pain-related cognitive processes as predictors were performed. Results: Lower stress, anxiety and depressive symptoms along with reduced pain catastrophism, psychological inflexibility and perceived control over pain were found in the low-impact group. Significant predictors of group membership (low-impact vs. moderate-to-high impact) in regression analyses were "cognitive fusion" (psychological inflexibility), "helplessness" (pain catastrophizing) and depressive symptomatology, together with pain intensity and other FM symptoms. Conclusions: The present study provides further evidence on resilience resources in chronic pain by identifying some variables (i.e. reduced depressive symptomatology, pain catastrophizing and psychological inflexibility) differentially characterizing a profile of FM patients who are especially able to adapt to high levels of pain.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Peripheral immune aberrations in fibromyalgia, a systematic review, meta-analysis and meta-regression

  • Andrés Rodríguez, Laura|||0000-0001-5133-9811
  • Borràs, Xavier|||0000-0003-3972-1385
  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Pérez-Aranda, Adrián|||0000-0002-1602-3413
  • Angarita-Osorio, Natalia|||0000-0001-8925-2754
  • Moreno-Peral, Patricia|||0000-0003-4130-9090
  • Montero-Marín, Jesús|||0000-0001-5677-1662
  • Garcia-Campayo, Javier|||0000-0002-3797-4218
  • Carvalho, André F.
  • Maes, Michael|||0000-0002-2012-871X
  • Luciano, Juan Vicente|||0000-0003-0750-1599
The objective was to identify immune alterations in patients with fibromyalgia syndrome (FMS) compared to healthy controls (HC) using meta-analysis and meta-regression. Six electronic databases were searched for suitable original articles investigating immune biomarkers in FMS in comparison to HC. We extracted outcomes and variables of interest, such as mean and SD of peripheral blood immune biomarkers, age or sex. A random-effects model with restricted maximum-likelihood estimator was used to compute effect sizes (standardized mean difference and 95% CI, Hedges' g) and meta-analysis, group meta-analysis and meta-regressions were conducted. Forty-three papers were included in this systematic review, of which 29 were suitable for meta-analysis. Interleukin (IL)-6 (g = 0.36 (0.09-0.63); I2 = 85.94; p = 0.01), IL-4 (g = 0.50 (0.03-0.98); I2 = 81.87; p = 0.04), and IL-17A (g = 0.53 (0.00-1.06); I2 = 87.15; p = 0.05), were significantly higher in FMS compared to HC while also combinations of cytokines into relevant phenotypes were significantly upregulated including M1 macrophage (g = 0.23 (0.03-0.43); I2 = 77.62; p = 0.02), and immune-regulatory (g = 0.40 (0.09-0.72); I2 = 84.81; p = 0.01) phenotypes. Heterogeneity levels were very high and subgroup and meta-regression analyses showed that many covariates explained part of the heterogeneity including medication washout, sex, time of blood sampling and exclusion of patients with major depressive disorder. In conclusion, FMS is accompanied by a disbalance between upregulated pro-inflammatory (M1 and Th-17) and immune-regulatory cytokines although effect sizes are small-to-moderate. Based on our results we provide specific methodological suggestions for future research, which should assess Th-1, Th-17, chemokines, and Th-2 phenotypes while controlling for possible confounding variables specified in this study.